BioCryst Announced Data Showing Reductions In Attack Rates In HAE Patients With Normal C1-Inhibitor After Beginning ORLADEYO Treatment
BioCryst Announced Data Showing Reductions In Attack Rates In HAE Patients With Normal C1-Inhibitor After Beginning ORLADEYO Treatment
BioCryst 公布的数据显示，在开始 ORLADEYO 治疗后，使用正常 C1 抑制剂的 HAE 患者的发作率有所降低
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced new real-world evidence showing that patients with hereditary angioedema (HAE) who have normal C1-inhibitor (HAE-nC1-INH) level and function had a reduction in monthly attack rates after starting oral, once-daily ORLADEYO (berotralstat). The data were presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress in Valencia, Spain.
BioCryst Pharmaceuticals, Inc.（纳斯达克股票代码：BCRX）今天公布了新的现实证据，表明C1抑制剂（HAE-NC1-INH）水平和功能正常的遗传性血管性水肿（HAE）患者在开始口服、每日一次的ORLADEYO（berotralstat）后，每月发作率有所降低。这些数据已在西班牙瓦伦西亚举行的欧洲过敏与临床免疫学学会（EAACI）大会上公布。